Minerva Neurosciences Inc Dossier - Source-backed chat

Minerva Neurosciences Inc

NERVNASDAQ

SectorHealth Care

IndustryBiotechnology

Beta (adjusted)1.00

Intrinsic Value

Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet.

Market Price $3.23Price as of 1 Oct 2026

Data confidenceNot applicable

Market Cap $154.2M

Enterprise Value $71.9M

Shares Outstanding 46.6M diluted

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

Minerva Neurosciences is a clinical-stage biopharmaceutical company focused on central nervous system (CNS) disorders. Its lead candidate, roluperidone, is being evaluated as a monotherapy for the negative symptoms of schizophrenia—an area with no currently approved FDA treatments. Following a Complete Response Letter (CRL) in February 2024, Minerva aligned with the FDA on a confirmatory Phase 3 trial design and secured up to $200 million in strategic financing (including $80 million upfront in October 2025). The company screened its first patient on March 31, 2026, with topline efficacy data expected in 2H 2027. While the clinical path is clear and funded, the stock remains a 'Hold' pending clinical execution and the high historical failure rate of negative symptom trials in schizophrenia.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets3 analysts · as of 18 Aug 2026

Low · most bearish analyst$7.00

Mean target$9.50

High · most bullish analyst$14.00

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 20 Jun 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

The confirmatory Phase 3 trial fails to show a statistically significant improvement in negative symptoms compared to placebo at 12 weeks, or safety concerns emerge during the co-administration or long-term monotherapy phases. The NDA cannot be resubmitted, and the company's valuation collapses to cash value.

Base CaseCentral scenario

The confirmatory Phase 3 trial successfully enrolls ~380 patients and meets its primary endpoint (change in PANSS Marder negative symptoms factor score at 12 weeks) in 2H 2027. This triggers the exercise of Tranche B warrants, providing $40 million in additional cash, and supports a successful NDA resubmission in 2028.

Bull CaseUpside scenario

Minerva Neurosciences represents a high-upside speculative growth opportunity centered on its lead drug candidate, roluperidone, for the treatment of negative symptoms in schizophrenia—a therapeutic area with no currently approved treatments in the U.S. or Europe. The bull case is supported by a clear regulatory path forward following alignment with the FDA on the design of its confirmatory Phase 3 trial, which initiated screening in March 2026 with topline efficacy data expected in 2H 2027. Furthermore, the company's financial runway is secured by an October 2025 private placement agreement valued at up to $200 million (including $80 million upfront and up to $120 million in potential additional proceeds from warrant exercises), providing the necessary capital to fund the Phase 3 trial, prepare for NDA resubmission, and advance commercial launch readiness.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

First-in-class potential: Roluperidone targets the negative symptoms of schizophrenia, a massive unmet medical need with zero FDA-approved therapies.
Secured funding: The October 2025 private placement provides up to $200 million (with $80 million upfront), which management expects is sufficient to fund operations through the Phase 3 trial and NDA resubmission.
FDA alignment: Clear regulatory path established with the FDA on trial design, endpoints, and patient selection criteria, reducing regulatory design risk.

Key Investment Risks

Clinical trial failure: Schizophrenia negative symptom trials have historically high failure rates across the industry.
Single-asset concentration: Minerva's valuation is heavily dependent on the clinical and regulatory success of roluperidone.
Dilution risk: Significant potential dilution from the conversion of Series A preferred stock and the exercise of outstanding Tranche A and B warrants.

Thesis Invalidation Triggers

Failure to meet the primary efficacy endpoint in the Phase 3 trial at 12 weeks.
Severe safety signals or high relapse rates observed during the 52-week observational phase.
Significant delays in patient enrollment pushing topline data readouts past 2H 2027.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.